newsfilter
← Latest News
ACCESS Newswire·

Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM)

- Xyngari is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ACCESSWIRE / December 16,